Corporate Profile
Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases, including cardiovascular and autoimmune diseases. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as coronary artery disease. A-623 targets elevated levels BLyS, which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus and others.
Recent ReleasesMay 3, 2012 Apr 27, 2012 |
|
||||||||||||||||||||
